Understanding Familial Hyperaldosteronism Type III (FH-III)

When you or your child are diagnosed with high blood pressure at an unusually young age, it can be a confusing time. Understanding the rare genetic root of FH-III can help clarify why standard treatments may not have worked. Familial Hyperaldosteronism Type III (FH-III) is a very rare genetic condition that causes the adrenal glands to produce too much aldosterone, a hormone that helps your body manage salt and water ^[1][2]. When aldosterone levels are too high, the body holds onto too much sodium and loses too much potassium, leading to severe high blood pressure (hypertension) ^[3][1].

While most cases of high aldosterone are “sporadic” (occurring by chance), FH-III is an inherited form caused by a specific mutation in the KCNJ5 gene ^[4][2]. It is much rarer than typical primary aldosteronism; while some registries find genetic forms in only 0.2% of all cases, only about 29 cases of FH-III have been documented in large-scale literature reviews ^[5][3]. (Note: These figures are derived from small historical series and registries, so the true incidence rate remains uncertain).

The Biological “Leaky Valve” (KCNJ5 Mutation)

To understand FH-III, it helps to think of the adrenal cells as having specialized “gates” called potassium channels. In a healthy person, these channels (specifically the Kir3.4 channel encoded by the KCNJ5 gene) only allow potassium to move through them ^[4]. This movement helps keep the cell’s electrical charge stable.

In FH-III, a mutation changes the shape of this gate, making it “leaky.” Instead of only letting potassium out, the gate starts letting sodium in ^[4][2]. This change in sodium levels causes the following chain reaction:

• Depolarization: The extra sodium changes the electrical charge of the cell membrane ^[2].
• Calcium Influx: This electrical change forces open other “calcium gates” (voltage-gated calcium channels) ^[4].
• Hormone Surge: The sudden rush of calcium into the cell acts as a “go” signal, telling the cell to produce massive amounts of aldosterone ^[4][2].

Because this mutation is in the “germline” (present in every cell from birth), the adrenal glands are constantly receiving this false signal to overproduce the hormone ^[1].

How FH-III Differs from Other Types

FH-III is distinct from both sporadic (non-inherited) disease and other familial types:

Comparison to Other FH Types

• FH-I (Glucocorticoid-Remediable Aldosteronism): Caused by a gene shuffle between two different genes. It is unique because it can be treated with steroids like dexamethasone.
• FH-II: The most common familial form. The CLCN2 gene explains some cases classified as FH-II, though not all ^[7].
• FH-IV: Associated with the CACNA1H gene. To interpret the risk, a specific variant must be classified as pathogenic (disease-causing), not merely found ^[3].

Clinical Signs and Challenges

The hallmark of classic FH-III is early-onset hypertension that is difficult to treat ^[1]. In pooled historical data, patients are diagnosed roughly 45 years earlier than the typical patient with sporadic primary aldosteronism ^[3].

Because the aldosterone levels are so high, the body loses a significant amount of potassium. This can cause symptoms like:

• Muscle weakness or cramping
• Extreme fatigue
• Frequent urination (especially at night)

In many patients with FH-III, the adrenal glands become physically larger on both sides (bilateral adrenal hyperplasia) ^[6]. Because the problem is throughout both glands, removing just one growth (which works for many other types of primary aldosteronism) often does not fix the problem ^[8]. However, imaging cannot reliably determine the cause or laterality, and cannot substitute for biochemical and genetic interpretation.

Treatment Realities

Managing FH-III is often more complex than managing other forms of high blood pressure. While mineralocorticoid-receptor antagonists (medications that block aldosterone) are the first choice, many FH-III patients find that these medications cannot keep up with the extreme hormone levels ^[2][9].

In some severe cases where medications fail to control blood pressure or protect the kidneys, doctors may discuss a bilateral adrenalectomy—the surgical removal of both adrenal glands ^[2][10]. While this cures the high aldosterone, it means the patient will need to take replacement adrenal hormones (like cortisol) for the rest of their life.

However, genotype-phenotype variability is substantial. Some “milder” versions of FH-III exist, potentially due to mosaicism (where only some cells have the mutation) or less aggressive variants. In these cases, medication might be enough to manage the condition for prolonged periods ^[10]. Testing for the specific mutation is essential to help your care team predict which path your treatment might take ^[11].

What is Known and What Remains Uncertain

Because FH-III is exceptionally rare, published evidence is limited largely to small families and case series. There is no universally predictable progression or genotype-based surgery rule, emphasizing the importance of personalized, expert care.